Skip to main content
Top
Published in: Current Atherosclerosis Reports 4/2014

01-04-2014 | Coronary Heart Disease (JA Farmer, Section Editor)

Screening Low-Risk Individuals for Coronary Artery Disease

Authors: Chintan S. Desai, Roger S. Blumenthal, Philip Greenland

Published in: Current Atherosclerosis Reports | Issue 4/2014

Login to get access

Abstract

A large proportion of cardiovascular events occur in individuals classified by traditional risk factors as “low-risk.” Efforts to improve early detection of coronary artery disease among low-risk individuals, or to improve risk assessment, might be justified by this large population burden. The most promising tests for improving risk assessment, or early detection, include the coronary artery calcium (CAC) score, the ankle-brachial index (ABI), and the high-sensitivity C-reactive protein (hsCRP). Data regarding the role of additional testing in low-risk populations to improve early detection or to enhance risk assessment are sparse but suggest that CAC and ABI may be helpful for improving risk classification and detecting the higher-risk people from among those at lower risk. However, in the absence of clinical trials in this patient population, such as has recently been proposed, we do not recommend routine use of any additional testing or screening in low-risk individuals at this time.
Literature
1.
go back to reference Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med. 2007;356(23):2388–98.PubMedCrossRef Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med. 2007;356(23):2388–98.PubMedCrossRef
2.
go back to reference Ford ES, Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. J Am Coll Cardiol. 2007;50(22):2128–32.PubMedCrossRef Ford ES, Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. J Am Coll Cardiol. 2007;50(22):2128–32.PubMedCrossRef
3.
go back to reference Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.PubMedCrossRef Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.PubMedCrossRef
4.
go back to reference Force USPS. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151(7):474–82.CrossRef Force USPS. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151(7):474–82.CrossRef
5.
go back to reference Shah PK. Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we? J Am Coll Cardiol. 2010;56(2):98–105.PubMedCrossRef Shah PK. Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we? J Am Coll Cardiol. 2010;56(2):98–105.PubMedCrossRef
6.
go back to reference Lauer MS. Screening asymptomatic subjects for subclinical atherosclerosis: not so obvious. J Am Coll Cardiol. 2010;56(2):106–8.PubMedCrossRef Lauer MS. Screening asymptomatic subjects for subclinical atherosclerosis: not so obvious. J Am Coll Cardiol. 2010;56(2):106–8.PubMedCrossRef
7.
go back to reference Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA J Am Med Assoc. 2001;285(19):2486–97.CrossRef Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA J Am Med Assoc. 2001;285(19):2486–97.CrossRef
8.
go back to reference Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.PubMedCrossRef Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.PubMedCrossRef
9.
go back to reference Califf RM, Armstrong PW, Carver JR, D’Agostino RB, Strauss WE. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol. 1996;27(5):1007–19.PubMedCrossRef Califf RM, Armstrong PW, Carver JR, D’Agostino RB, Strauss WE. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol. 1996;27(5):1007–19.PubMedCrossRef
10.
go back to reference Rose G. Sick individuals and sick populations. Int J Epidemiol. 2001;30(3):427–32. discussion 433–424.PubMedCrossRef Rose G. Sick individuals and sick populations. Int J Epidemiol. 2001;30(3):427–32. discussion 433–424.PubMedCrossRef
11.
go back to reference Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.PubMedCrossRef Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.PubMedCrossRef
12.
go back to reference Cooney MT, Dudina A, Whincup P, et al. Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. Eur J Cardiovasc Prev Rehabil Off J Eur Soc Cardiol Work Group Epidemiol Prev Card Rehabil Exerc Physiol. 2009;16(5):541–9. Cooney MT, Dudina A, Whincup P, et al. Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. Eur J Cardiovasc Prev Rehabil Off J Eur Soc Cardiol Work Group Epidemiol Prev Card Rehabil Exerc Physiol. 2009;16(5):541–9.
14.••
go back to reference Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122(25):e584-636. This is an important review of all potential approaches to risk assessment in asymptomatic patients. It is a good source of detailed background on this subject. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122(25):e584-636. This is an important review of all potential approaches to risk assessment in asymptomatic patients. It is a good source of detailed background on this subject.
15.••
go back to reference Anderson TJ, Gregoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29(2):151–67. This update to previous Canadian Guidelines is an important reference source on the topics of prevention and risk assessment. Anderson TJ, Gregoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29(2):151–67. This update to previous Canadian Guidelines is an important reference source on the topics of prevention and risk assessment.
16.
go back to reference Libby P, Ridker PM, Hansson GK, Leducq Transatlantic Network on A. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129–38.PubMedCentralPubMedCrossRef Libby P, Ridker PM, Hansson GK, Leducq Transatlantic Network on A. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129–38.PubMedCentralPubMedCrossRef
17.
go back to reference Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959–65.PubMedCrossRef Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959–65.PubMedCrossRef
18.
go back to reference Sever PS, Poulter NR, Chang CL, et al. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the anglo-scandinavian cardiac outcomes trial lipid-lowering arm. J Am Coll Cardiol. 2013;62(8):717–29.PubMedCrossRef Sever PS, Poulter NR, Chang CL, et al. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the anglo-scandinavian cardiac outcomes trial lipid-lowering arm. J Am Coll Cardiol. 2013;62(8):717–29.PubMedCrossRef
19.
go back to reference Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol. 2003;92(4B):17K–22K.PubMedCrossRef Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol. 2003;92(4B):17K–22K.PubMedCrossRef
20.••
go back to reference Yousuf O, Mohanty BD, Martin SS, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62(5):397–408. This is a comprehensive review of the utility of C-reactive protein for cardiovascular risk. It supports a limited role for hsCRP in risk assessment. Yousuf O, Mohanty BD, Martin SS, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62(5):397–408. This is a comprehensive review of the utility of C-reactive protein for cardiovascular risk. It supports a limited role for hsCRP in risk assessment.
21.
go back to reference Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310–20.PubMedCrossRef Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310–20.PubMedCrossRef
22.
go back to reference Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004;109(11):1349–53.PubMedCrossRef Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004;109(11):1349–53.PubMedCrossRef
23.
go back to reference Ankle Brachial Index C, Fowkes FG, Murray GD, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA J Am Med Assoc. 2008;300(2):197–208.CrossRef Ankle Brachial Index C, Fowkes FG, Murray GD, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA J Am Med Assoc. 2008;300(2):197–208.CrossRef
24.
go back to reference Mohlenkamp S, Lehmann N, Moebus S, et al. Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. J Am Coll Cardiol. 2011;57(13):1455–64.PubMedCrossRef Mohlenkamp S, Lehmann N, Moebus S, et al. Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. J Am Coll Cardiol. 2011;57(13):1455–64.PubMedCrossRef
25.••
go back to reference Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA J Am Med Assoc. 2012;308(8):788–95. This is one of a small number of analyses from a large cohort comparing risk assessment approaches using different tests. It supports a conclusion that CAC is the leading contender for improving risk assessment in intermediate risk populations. Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA J Am Med Assoc. 2012;308(8):788–95. This is one of a small number of analyses from a large cohort comparing risk assessment approaches using different tests. It supports a conclusion that CAC is the leading contender for improving risk assessment in intermediate risk populations.
26.
go back to reference Pencina MJ, D’Agostino Sr RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(1):11–21.PubMedCentralPubMedCrossRef Pencina MJ, D’Agostino Sr RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(1):11–21.PubMedCentralPubMedCrossRef
27.••
go back to reference Kavousi M, Elias-Smale S, Rutten JH, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med. 2012;156(6):438–44. This paper is similar to reference 26 but applies across the entire Rotterdam cohort of mostly elderly men and women. Kavousi M, Elias-Smale S, Rutten JH, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med. 2012;156(6):438–44. This paper is similar to reference 26 but applies across the entire Rotterdam cohort of mostly elderly men and women.
28.
go back to reference Lakoski SG, Greenland P, Wong ND, et al. Coronary artery calcium scores and risk for cardiovascular events in women classified as “low risk” based on Framingham risk score: the multi-ethnic study of atherosclerosis (MESA). Arch Intern Med. 2007;167(22):2437–42.PubMedCrossRef Lakoski SG, Greenland P, Wong ND, et al. Coronary artery calcium scores and risk for cardiovascular events in women classified as “low risk” based on Framingham risk score: the multi-ethnic study of atherosclerosis (MESA). Arch Intern Med. 2007;167(22):2437–42.PubMedCrossRef
29.
go back to reference Mohlenkamp S, Lehmann N, Greenland P, et al. Coronary artery calcium score improves cardiovascular risk prediction in persons without indication for statin therapy. Atherosclerosis. 2011;215(1):229–36.PubMedCrossRef Mohlenkamp S, Lehmann N, Greenland P, et al. Coronary artery calcium score improves cardiovascular risk prediction in persons without indication for statin therapy. Atherosclerosis. 2011;215(1):229–36.PubMedCrossRef
30.
go back to reference Desai CS, Ayers CR, Budoff M, et al. Improved coronary heart disease risk prediction with coronary artery calcium in low-risk women: a meta-analysis of four cohorts. J Am Coll Cardiol. 2013;61(10):E995–5. Desai CS, Ayers CR, Budoff M, et al. Improved coronary heart disease risk prediction with coronary artery calcium in low-risk women: a meta-analysis of four cohorts. J Am Coll Cardiol. 2013;61(10):E995–5.
31.
32.
go back to reference Bhatti SK, Dinicolantonio JJ, Captain BK, Lavie CJ, Tomek A, O’Keefe JH. Neutralizing the adverse prognosis of coronary artery calcium. Mayo Clin Proc Mayo Clin. 2013;88(8):806–12.CrossRef Bhatti SK, Dinicolantonio JJ, Captain BK, Lavie CJ, Tomek A, O’Keefe JH. Neutralizing the adverse prognosis of coronary artery calcium. Mayo Clin Proc Mayo Clin. 2013;88(8):806–12.CrossRef
33.
go back to reference Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90.PubMedCrossRef Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90.PubMedCrossRef
34.•
go back to reference Ambrosius WT, Polonsky TS, Greenland P, et al. Design of the value of imaging in enhancing the wellness of your heart (VIEW) trial and the impact of uncertainty on power. Clin Trials. 2012;9(2):232–46. This is a provocative proposal for a large-scale trial of coronary artery calcium testing (screening) in asymptomatic low-risk individuals. It is an important “thought-piece” on this topic. Ambrosius WT, Polonsky TS, Greenland P, et al. Design of the value of imaging in enhancing the wellness of your heart (VIEW) trial and the impact of uncertainty on power. Clin Trials. 2012;9(2):232–46. This is a provocative proposal for a large-scale trial of coronary artery calcium testing (screening) in asymptomatic low-risk individuals. It is an important “thought-piece” on this topic.
Metadata
Title
Screening Low-Risk Individuals for Coronary Artery Disease
Authors
Chintan S. Desai
Roger S. Blumenthal
Philip Greenland
Publication date
01-04-2014
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 4/2014
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-014-0402-8

Other articles of this Issue 4/2014

Current Atherosclerosis Reports 4/2014 Go to the issue

Coronary Heart Disease (JA Farmer, Section Editor)

Pathophysiology of Acute Coronary Syndrome

Vascular Biology (RS Rosenson, Section Editor)

Vascular Imaging in Diabetes

Coronary Heart Disease (JA Farmer, Section Editor)

Modulation of the Renin-Angiotensin-Aldosterone System in Heart Failure

Nonstatin Drugs (WB Borden, Section Editor)

HDL Hypothesis: Where Do We Stand Now?

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine